These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 35169793)

  • 1. SARS-CoV-2 variant of concern type and biological sex affect efficacy of molnupiravir in dwarf hamster model of severe COVID-19.
    Lieber CM; Cox RM; Sourimant J; Wolf JD; Juergens K; Phung Q; Saindane MT; Natchus MG; Painter GR; Sakamoto K; Greninger AL; Plemper RK
    bioRxiv; 2022 Feb; ():. PubMed ID: 35169793
    [TBL] [Abstract][Full Text] [Related]  

  • 2. SARS-CoV-2 VOC type and biological sex affect molnupiravir efficacy in severe COVID-19 dwarf hamster model.
    Lieber CM; Cox RM; Sourimant J; Wolf JD; Juergens K; Phung Q; Saindane MT; Smith MK; Sticher ZM; Kalykhalov AA; Natchus MG; Painter GR; Sakamoto K; Greninger AL; Plemper RK
    Nat Commun; 2022 Jul; 13(1):4416. PubMed ID: 35906230
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Paxlovid-like nirmatrelvir/ritonavir fails to block SARS-CoV-2 transmission in ferrets.
    Cox RM; Lieber CM; Wolf JD; Karimi A; Lieberman NAP; Sticher ZM; Roychoudhury P; Andrews MK; Krueger RE; Natchus MG; Painter GR; Kolykhalov AA; Greninger AL; Plemper RK
    bioRxiv; 2022 Nov; ():. PubMed ID: 36451893
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molnupiravir (MK-4482) is efficacious against Omicron and other SARS-CoV-2 variants in the Syrian hamster COVID-19 model.
    Rosenke K; Okumura A; Lewis MC; Feldmann F; Meade-White K; Bohler WF; Griffin A; Rosenke R; Shaia C; Jarvis MA; Feldmann H
    bioRxiv; 2022 Feb; ():. PubMed ID: 35233571
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molnupiravir inhibits SARS-CoV-2 variants including Omicron in the hamster model.
    Rosenke K; Okumura A; Lewis MC; Feldmann F; Meade-White K; Bohler WF; Griffin A; Rosenke R; Shaia C; Jarvis MA; Feldmann H
    JCI Insight; 2022 Jul; 7(13):. PubMed ID: 35579953
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pathogenicity, transmissibility, and fitness of SARS-CoV-2 Omicron in Syrian hamsters.
    Yuan S; Ye ZW; Liang R; Tang K; Zhang AJ; Lu G; Ong CP; Man Poon VK; Chan CC; Mok BW; Qin Z; Xie Y; Chu AW; Chan WM; Ip JD; Sun H; Tsang JO; Yuen TT; Chik KK; Chan CC; Cai JP; Luo C; Lu L; Yip CC; Chu H; To KK; Chen H; Jin DY; Yuen KY; Chan JF
    Science; 2022 Jul; 377(6604):428-433. PubMed ID: 35737809
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SARS-CoV-2 Omicron variant causes mild pathology in the upper and lower respiratory tract of hamsters.
    Armando F; Beythien G; Kaiser FK; Allnoch L; Heydemann L; Rosiak M; Becker S; Gonzalez-Hernandez M; Lamers MM; Haagmans BL; Guilfoyle K; van Amerongen G; Ciurkiewicz M; Osterhaus ADME; Baumgärtner W
    Nat Commun; 2022 Jun; 13(1):3519. PubMed ID: 35725735
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SARS-CoV-2 Omicron (B.1.1.529) Variant: A Challenge with COVID-19.
    Mohseni Afshar Z; Tavakoli Pirzaman A; Karim B; Rahimipour Anaraki S; Hosseinzadeh R; Sanjari Pireivatlou E; Babazadeh A; Hosseinzadeh D; Miri SR; Sio TT; Sullman MJM; Barary M; Ebrahimpour S
    Diagnostics (Basel); 2023 Feb; 13(3):. PubMed ID: 36766664
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pathogenicity of SARS-CoV-2 Omicron (R346K) variant in Syrian hamsters and its cross-neutralization with different variants of concern.
    Mohandas S; Yadav PD; Sapkal G; Shete AM; Deshpande G; Nyayanit DA; Patil D; Kadam M; Kumar A; Mote C; Jain R
    EBioMedicine; 2022 May; 79():103997. PubMed ID: 35405385
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Why Does the SARS-CoV-2 Delta VOC Spread So Rapidly? Universal Conditions for the Rapid Spread of Respiratory Viruses, Minimum Viral Loads for Viral Aerosol Generation, Effects of Vaccination on Viral Aerosol Generation, and Viral Aerosol Clouds.
    Lee BU
    Int J Environ Res Public Health; 2021 Sep; 18(18):. PubMed ID: 34574724
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antiviral Efficacy and Safety of Molnupiravir Against Omicron Variant Infection: A Randomized Controlled Clinical Trial.
    Zou R; Peng L; Shu D; Zhao L; Lan J; Tan G; Peng J; Yang X; Liu M; Zhang C; Yuan J; Wang H; Li S; Lu H; Zhong W; Liu Y
    Front Pharmacol; 2022; 13():939573. PubMed ID: 35784723
    [No Abstract]   [Full Text] [Related]  

  • 12. Combination of the parent analogue of remdesivir (GS-441524) and molnupiravir results in a markedly potent antiviral effect in SARS-CoV-2 infected Syrian hamsters.
    Abdelnabi R; Maes P; de Jonghe S; Weynand B; Neyts J
    Front Pharmacol; 2022; 13():1072202. PubMed ID: 36605401
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Update on SARS-CoV-2 Omicron Variant of Concern and Its Peculiar Mutational Profile.
    Alkhatib M; Salpini R; Carioti L; Ambrosio FA; D'Anna S; Duca L; Costa G; Bellocchi MC; Piermatteo L; Artese A; Santoro MM; Alcaro S; Svicher V; Ceccherini-Silberstein F
    Microbiol Spectr; 2022 Apr; 10(2):e0273221. PubMed ID: 35352942
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combined molnupiravir-nirmatrelvir treatment improves the inhibitory effect on SARS-CoV-2 in macaques.
    Rosenke K; Lewis MC; Feldmann F; Bohrnsen E; Schwarz B; Okumura A; Bohler WF; Callison J; Shaia C; Bosio CM; Lovaglio J; Saturday G; Jarvis MA; Feldmann H
    JCI Insight; 2023 Feb; 8(4):. PubMed ID: 36574296
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The omicron (B.1.1.529) SARS-CoV-2 variant of concern does not readily infect Syrian hamsters.
    Abdelnabi R; Foo CS; Zhang X; Lemmens V; Maes P; Slechten B; Raymenants J; André E; Weynand B; Dallmeier K; Neyts J
    Antiviral Res; 2022 Feb; 198():105253. PubMed ID: 35066015
    [TBL] [Abstract][Full Text] [Related]  

  • 16. SARS-CoV-2 Variants of Concern Hijack IFITM2 for Efficient Replication in Human Lung Cells.
    Nchioua R; Schundner A; Kmiec D; Prelli Bozzo C; Zech F; Koepke L; Graf A; Krebs S; Blum H; Frick M; Sparrer KMJ; Kirchhoff F
    J Virol; 2022 Jun; 96(11):e0059422. PubMed ID: 35543509
    [TBL] [Abstract][Full Text] [Related]  

  • 17. VSV-Based Vaccines Reduce Virus Shedding and Viral Load in Hamsters Infected with SARS-CoV-2 Variants of Concern.
    O'Donnell KL; Gourdine T; Fletcher P; Shifflett K; Furuyama W; Clancy CS; Marzi A
    Vaccines (Basel); 2022 Mar; 10(3):. PubMed ID: 35335067
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Roborovski Dwarf Hamster Is A Highly Susceptible Model for a Rapid and Fatal Course of SARS-CoV-2 Infection.
    Trimpert J; Vladimirova D; Dietert K; Abdelgawad A; Kunec D; Dökel S; Voss A; Gruber AD; Bertzbach LD; Osterrieder N
    Cell Rep; 2020 Dec; 33(10):108488. PubMed ID: 33271063
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combined Molnupiravir and Nirmatrelvir Treatment Improves the Inhibitory Effect on SARS-CoV-2 in Rhesus Macaques.
    Rosenke K; Lewis MC; Feldmann F; Bohrnsen E; Schwarz B; Okumura A; Bohler WF; Callison J; Shaia C; Bosio CM; Lovaglio J; Saturday G; Jarvis MA; Feldmann H
    bioRxiv; 2022 Sep; ():. PubMed ID: 36263071
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molnupiravir-A Novel Oral Anti-SARS-CoV-2 Agent.
    Lee CC; Hsieh CC; Ko WC
    Antibiotics (Basel); 2021 Oct; 10(11):. PubMed ID: 34827232
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.